Valuation: United Therapeutics Corporation

Market Cap 22.01B 18.85B 17.64B 16.15B 30.3B 2,106B 30.7B 208B 81.27B 1,058B 82.64B 80.84B 3,499B P/E 2026 *
19.7x
P/E 2027 * 17.9x
Enterprise Value 19.04B 16.31B 15.26B 13.97B 26.21B 1,821B 26.56B 180B 70.29B 915B 71.48B 69.92B 3,026B EV / Sales 2026 *
6.07x
EV / Sales 2027 * 5.29x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day-1.51%
1 week+2.68%
Current month-0.89%
1 month-3.10%
3 months-9.73%
6 months+8.13%
Current year+5.31%
1 week 508.56
Extreme 508.56
535.77
1 month 490.8
Extreme 490.8
541.03
Current year 455.63
Extreme 455.63
609.35
1 year 302.19
Extreme 302.19
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 26/06/1996
President 54 26/06/2016
Director of Finance/CFO 58 13/03/2015
Director TitleAgeSince
Director/Board Member 78 01/01/2002
Chairman 71 26/06/1996
Director/Board Member 92 01/01/2002
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Fiscal year

General Counsel

24,900 0.0587%
20/08/26 Fiscal year

Chief Executive Officer

28,500 0.0671%
19/08/26 Fiscal year

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%+2.68%+64.34%+121.69% 22.01B
+0.88%+6.38%+76.40%+126.87% 1,119B
+1.07%+3.80%+50.73%+64.25% 651B
+1.20%+6.21%+25.81%+80.15% 468B
-1.16%+4.04%+42.55%+42.42% 374B
-0.28%+2.85%+25.37%+41.24% 302B
-0.91%+4.84%+2.09%+12.74% 259B
+1.29%+5.81%+49.57%+70.71% 238B
+0.52%+3.11%-17.91%-53.31% 208B
+1.87%+5.61%+27.32%+89.67% 181B
Average +0.30%+4.92%+34.63%+59.64% 382.19B
Weighted average by Cap. +0.58%+5.38%+44.26%+72.63%

Financials

2026 *2027 *
Net sales 3.14B 2.69B 2.52B 2.3B 4.32B 300B 4.38B 29.72B 11.59B 151B 11.78B 11.53B 499B 3.44B 2.95B 2.76B 2.53B 4.74B 329B 4.8B 32.6B 12.71B 165B 12.93B 12.65B 547B
Net income 1.2B 1.03B 960M 879M 1.65B 115B 1.67B 11.34B 4.42B 57.55B 4.5B 4.4B 190B 1.32B 1.13B 1.06B 967M 1.81B 126B 1.84B 12.48B 4.87B 63.33B 4.95B 4.84B 209B
Net Debt -2.97B -2.55B -2.38B -2.18B -4.09B -284B -4.15B -28.15B -10.98B -143B -11.16B -10.92B -473B -3.81B -3.26B -3.05B -2.79B -5.24B -364B -5.31B -36.04B -14.05B -183B -14.29B -13.98B -605B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
21/08/26 $513.12 -1.51% 415,573
20/08/26 $521.00 -1.54% 440,385
19/08/26 $529.14 +2.10% 432,111
18/08/26 $518.27 +1.93% 366,432
17/08/26 $508.48 +1.75% 457,341
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
513.12USD
Average target price
664.33USD
Spread / Average Target
+29.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock